AI Health Kiosk Network

Problem PitchWe are working to solve the problem of scaling trusted, low-friction preventive screening across public-facing locations for hospitals and private clinics, who struggle with low follow-through, trust delays, and weak payback, because buyers now want earlier detection and easier access without adding staff.

This is not just a device or software issue; it combines behavior change, buyer trust, site operations, and multi-stakeholder economics across healthcare, education, and government.

• Pharmacy foot-traffic monetization
• School health compliance
• Government population screening
• Local discovery and walk-in access
• Repeat health tracking

• Screening is inconvenient
• Value is not immediate
• Trust is hard to establish
• Operations are hard to standardize
• Discovery depends on location and habit

A recurring preventive-screening problem where buyers need a scalable way to get people checked quickly, trust the results, and turn one-time curiosity into repeated use

Problem PitchWe are working to solve the problem of scaling trusted, low-friction preventive screening across public-facing locations for hospitals and private clinics, who struggle with low follow-through, trust delays, and weak payback, because buyers now want earlier detection and easier access without adding staff.

• Use pharmacies as distribution points and as local trust anchors.
• Turn the basic check into the free hook and sell the report.
• Sell city deals as managed screening capacity, not devices.

Solution PitchOur solution helps clinics and hospitals give patients fast screening and follow-up by turning a hosted kiosk into a free entry point and paid report engine, unlike manual front-desk checks.

Wedge first into private clinics and pharmacy-hosted sites in Egypt and Saudi Arabia; build the moat around local discovery plus recurring screening data; test in 90 days by launching 10 hosted kiosks, targeting 30% monthly active usage and 15% paid upgrade conversion.

The biggest migration trigger is convenience plus trust; engineer it with pharmacy-hosted trial kiosks and Google Maps discovery campaigns.

Global market is all clinics, hospitals, pharmacies, schools, and governments that could buy screening kiosks; this is conservative using the project's 3-minute BP/BMI/eyesight kiosk plus software and services, not full diagnostics.

The founder only operates in Egypt and Saudi Arabia and sells mainly to private clinics/hospitals, with schools and governments as secondary buyers; I limited SAM to those two countries and the clinic-led channel.

In 3 years, a solo founder with founder-led WhatsApp/local-search sales, a technical cofounder search, and 2-6 week sales cycles can plausibly win a small set of clinics plus a few multi-kiosk sites; this is conservative.

Preventive screening kiosks should grow steadily but not explosively; I used a moderate growth rate reflecting AI health screening, hardware adoption, and the project's existing paid customers in Egypt and Saudi Arabia.

Using the pricing strategy, the core offer is SAR 499/month per kiosk, which is about SAR 5,988/year; adding setup, reports, subscriptions, and ads lifts annual revenue per active customer/site to a conservative average.

The smartest starting mix is not a retail store network; it is a hub-and-spoke model. Put manufacturing and fulfillment in an industrial zone in Egypt for cost control and service speed, keep commercial selling in New Cairo and Riyadh for buyer access, and use distribution partners like pharmacies, hospitals, clinics, schools, and government entities to place kiosks where screening demand already exists. For this business, the winning sequence is: build operational reliability first, then win institutional buyers, then expand hosted placements through channel partners. Avoid opening consumer-facing locations before the compliance, calibration, and procurement motion is proven.

The current location logic is strong because it matches the actual operating model: this is not a storefront business, it is a hardware-plus-channel distribution business. The main gap is that the founder may be tempted to overinvest in visible commercial locations before locking compliance, calibration, and partner economics. The best correction is to keep the commercial hubs lean and use them only for selling and relationship management, while the industrial base does the heavy lifting. Another risk is underestimating Saudi procurement cycles; Riyadh should be treated as a relationship and enterprise-sales hub, not a mass-market launch city.

Start with a two-country operating model: keep production and fulfillment in 6th of October City or 10th of Ramadan, run Egypt commercial selling from New Cairo, and run Saudi enterprise selling from Riyadh Al Olaya. Use pharmacies, hospitals, clinics, schools, and government institutions as channel partners rather than trying to build consumer retail stores. Sequence: 1) lock the Egypt pilot and reference accounts in New Cairo, 2) close Saudi enterprise buyers from Riyadh, 3) scale hardware assembly and QA from the industrial base, 4) expand hosted kiosks through pharmacy revenue-share partnerships, 5) add Jeddah only after Riyadh traction is repeatable.

• Exact regulatory classification for blood pressure, BMI, eyesight, AI scoring, and phone-result delivery in Saudi Arabia and Egypt still needs a local legal memo.
• No confirmed site-level budget was provided for rent, fit-out, or manufacturing capex, so the rent forecast is directional only.
• No confirmed shortlist of host partners was provided, so channel rollout assumptions should be validated with pilot LOIs before expansion.

Signal strength is very weak because there are no recorded KOL interviews, no named experts, and no direct validation quotes. At this stage the evidence is only a founder narrative plus inferred market logic, so investors should treat everything as hypothesis, not proof. Sample-quality concerns are severe: there is no mix of buyer types, no clinical voices, no procurement voices, and no regulatory voices. The business spans hospitals, clinics, schools, governments, pharmacies, and end users across two countries, but none of those segments has been independently validated in the log. The strongest recurring objection to expect is regulatory and claims risk: whether this is a wellness kiosk, a screening tool, or a medical device-adjacent product. Closely behind that is buyer skepticism about whether institutions will actually pay, host, maintain, and trust the kiosk at scale. In the next 3 interviews, test three things: first, whether a hospital or clinic buyer would pay and where the kiosk fits in workflow; second, whether a regulator, compliance lawyer, or medical device expert would classify the claims as acceptable; third, whether a pharmacy or school host would accept the operational burden and revenue-share model. Capture exact objections, willingness to pilot, and the minimum proof required to move forward.

• The concept appears to fit a real need for fast, low-friction screening that can be deployed in public-facing locations.
• Hospitals, clinics, schools, and governments are plausible buyers for a kiosk-based screening product.
• The hardware-plus-software model could be differentiated if it reliably delivers results in about 3 minutes and sends them to the phone.
• Compliance, claims discipline, and privacy controls will likely be critical before any broader rollout.
• Channel partnerships such as pharmacies hosting kiosks with revenue share look like a plausible distribution path.

• There is no interview log, so there is no evidence of real KOL agreement or disagreement yet.
• The founder positions the product as both a patient-paid consumer service and a B2B institutional sale, but the strongest buyer motion is still untested.
• The traction claim of about 18% upgrade conversion is promising, but it is unclear whether that reflects paid conversion, repeat use, or a pilot-specific anomaly.
• The regulatory posture could range from wellness screening to regulated medical device behavior, and that boundary is not yet validated.

Win only if hospitals and clinics treat the kiosk as a paid front-door screening layer, not a gadget.

This is a SAR-priced, two-country kiosk network selling 3-minute screening plus paid reports and subscriptions, with Egypt and Saudi buyers as the first market assumption. I assumed a SAR 5,000–50,000 hardware sale/lease range and a SAR 5–25 per patient scan path; the biggest risk is whether buyers trust the readings and the compliance boundary.

• Local pharmacies hosting kiosks
• Clinic buyers in New Cairo and Riyadh
• SFDA and EDA compliance counsel
• A payment gateway like Paymob

• Install and calibrate kiosks weekly
• Sell into clinics and hospital lobbies
• Review claims, consent, and uptime
• Track upgrades from free check to paid

• Own sensors, camera, and kiosk shell
• AI screening software and phone handoff
• Pending patent and field calibration SOPs
• Solo founder; needs a technical co-founder

• 3-minute screening for BP, BMI, eyesight
• Free basic check, paid report, 18% upgrade
• Walk-in access in pharmacies and clinics
• Results sent straight to the patient's phone

• On-site setup and remote monitoring
• Monthly subscription for repeat users
• Host revenue share for pharmacies
• Clinic account manager by WhatsApp

• Google Maps and local search
• Direct sales to clinics and hospitals
• Pharmacy host referrals
• Riyadh and New Cairo buyer meetings

• Private clinics and hospitals
• Pharmacies hosting foot traffic
• Schools and universities
• City governments buying 20-50 kiosks

• Kiosk build: SAR 8,000-20,000/unit
• Calibration and spares: SAR 500-1,500/mo
• New Cairo and Riyadh sales travel: SAR 2,000-6,000/mo
• Legal, privacy, and SFDA/EDA review: SAR 4,000-12,000

• Kiosk sale or lease: SAR 5,000-50,000
• Patient paid report: SAR 5-25/scan
• Monthly tracking: SAR 15-40/mo
• Host ads and revenue share placements

Hospitals and clinics can screen 3 minutes faster, but only if they trust the readings and the payback.

Assumption: Egypt and Saudi Arabia, with private clinics as the first buyer and pharmacies as hosted distribution points. The offer wins when buyers see the kiosk as a front-door screening tool that creates paid report upgrades and repeat tracking, not just a machine. Biggest fit risk: trust in readings and clinical claims is still the bottleneck, so today’s fit is real but not fully proven at scale.

Promising for live pilots and early sales, but not yet strong enough to rely on trust alone for broad scale.

For private clinics and hospitals who need to screen more people without adding staff, AI Health Kiosk Network is the 3-minute screening kiosk that sends results to the phone and turns free checks into paid reports, unlike manual vitals and ad hoc nurse screening which get skipped when the line is busy.

Get to a 100-unit pilot with off-the-shelf electronics, then freeze the enclosure before any tooling or import commitments.

Assumption: Egypt and Saudi Arabia, with SAR as the reporting currency and a mix of local assembly plus imported sensors, camera, and compute from Shenzhen or LCSC/Mouser. You do not yet have an electronics or mechanical engineer, so the biggest cash risk is paying for custom tooling or a large parts MOQ before the design is validated and compliant.

1) Build 1 bench unit with off-the-shelf parts and log 50 scans; 2) get a Cairo job shop quote for a no-tooling enclosure; 3) hire a contract electronics/mechanical designer for SAR 8,000-SAR 15,000; 4) request SFDA and EDA classification guidance; 5) collect 10 buyer sign-offs from clinics in New Cairo and Riyadh.

SAR reporting; PCBA assembled in Shenzhen for 1 and 100 units, then mixed local assembly plus imported PCBA at 1k and 10k; tooling is deferred until after 100-unit pilot.

A 3-country kiosk chain with 4-week import legs and SAR 169,000 tied up in the first pilot stock order.

Assumption: 100-kiosk pilot demand across Egypt and Saudi clinics/pharmacies, with monthly replacement and spares driven by live pilots, not mass rollout. Biggest risk: custom electronics and imported modules can stall on SFDA/EDA review and Nafeza/ACID customs, leaving dead stock or delayed installs.

1) Buy 1 sample electronics set and log 50 bench scans; 2) get 2 quotes for enclosures in 6th of October City; 3) secure 1 freight forwarder quote with ACID handling; 4) collect 10 clinic buyer sign-offs in New Cairo and Riyadh; 5) write the PO quality spec and 30/70 payment terms before any 10-unit order.

Legal to sell only after you secure medical-device, tax, and data approvals; setup compliance budget: SAR 24,000

Assumption: Egypt and Saudi Arabia, with a small hardware/software kiosk sold to clinics, schools, and governments, and fees for first registrations, legal review, and basic filings in SAR. The biggest legal risk right now is misclassifying the kiosk as a simple digital product when it is likely treated as a medical-device-adjacent system with health data and patient-facing claims.

1) File classification requests with SFDA and EDA and get written responses. 2) Register or clean up the Saudi and Egypt entities and activity codes. 3) Draft privacy notice, consent screen, host contract, and maintenance SLA. 4) Set up VAT and invoicing with an accountant. 5) Keep one pilot site only until the first approvals are in hand.

• Get SFDA and EDA classification guidance
• Clean up company registrations and activity codes
• Set up tax and invoicing
• Finalize privacy, consent, and host contracts
• Expand to schools and governments after clinic pilots are compliant

No-code MVP with SAR 0 launch tools and a 4-6 week path to pilot

This fits a solo, non-technical founder in Egypt and Saudi Arabia because it keeps the first version simple, manual, and fast to ship. I assumed SAR as the project currency and used tools that work with local payment and communication habits; the biggest risk is hitting the no-code ceiling once kiosk ops, device health, and multi-site reporting grow.

1) Build a Glide admin portal and log 100 scans in Sheets; 2) connect Paymob and collect 10 paid report payments; 3) create one Looker Studio dashboard for upgrade rate and uptime; 4) run 15 buyer calls and track who asks for a lease or subscription; 5) document the exact moment you need a rewrite if manual work exceeds 2 hours per day.

At launch, this stack can run for about SAR 0-SAR 238/mo using free tiers and WhatsApp Business. At 10k users, expect roughly SAR 1,050-SAR 1,890/mo unless you move from no-code tools to Supabase and paid messaging.

Protect the brand, lock the software and calibration know-how, and do not bet the company on a patent first.

Assumption: Egypt and Saudi Arabia, priced and budgeted in SAR. For this kiosk network, the real moat is trademark + trade secrets + copyright hygiene; a patent may be worth filing only if the hardware sensing method is genuinely novel and defensible. Biggest IP risk: a copycat can clone the concept faster than a patent can save it, especially if the brand, code, and operating playbook are not locked down now.

File the core marks in Saudi Arabia and Egypt first, then extend to any GCC market only when a host or franchise deal is real. Do not wait for perfect scale; brand squatting is cheaper to prevent than to fight.

License the brand and operating system only after the marks are filed and the franchise manual is locked. Keep the sensing software and calibration process as retained know-how, not open-sourced or broadly licensed.

1) File the Saudi and Egypt trademarks and get application numbers. 2) Sign NDAs and IP assignments with every contractor and advisor. 3) Move code, calibration docs, and supplier files into private access-controlled systems. 4) Do a novelty screen on the sensing method and decide yes/no on a narrow patent. 5) Prepare a franchise/IP pack for the next host and buyer meeting.

• Trademark in Saudi Arabia
• Trademark in Egypt
• NDA and IP assignment pack
• Trade-secret controls and private repos
• Patent only after novelty review

What is already repeatable is the core kiosk experience: a 3-minute screening flow, a fixed set of measurements, and instant phone delivery of results. The business also has a clear buyer pattern already emerging: private clinics and hospitals are the first serious customers, with pharmacies as hosted distribution points. Where the bespoke creep hides is in every layer around the machine: site-by-site procurement, compliance interpretation, calibration, host revenue-share terms, installation, support, and the sales motion across Egypt and Saudi Arabia. The moment you sell to schools or governments, the process becomes even more custom and slow. The leverage move is to productize one narrow offer and force everything else into a standard package: one kiosk, one buyer type, one installation checklist, one support SLA, one pricing page, one renewal motion. The business should stop selling “a health platform” and start selling “clinic screening kiosk with remote monitoring and patient report delivery.” An operator-led version of this business would look like a deployment machine, not a founder-driven custom project shop. A country manager would run a standard sales script, a field ops lead would handle installs and calibration, and a support desk would manage uptime and host issues from a playbook. The founder would only handle partnerships, compliance, and product decisions.

Clinic screening kiosk with remote monitoring and patient phone results

This is the tightest offer because it matches the strongest buyer segment, uses the existing 3-minute workflow, and cuts out schools, governments, ads, and custom enterprise features. It should be sold as one kiosk, one monthly fee, one install package, and one support plan.

• Regulatory classification and claims risk may force changes to the product and marketing language.
• Hardware assembly, calibration, and support are still founder-dependent and not yet systemized.
• Sales cycles are long and procurement-heavy, especially outside private clinics.
• Unit economics are fragile if installation, support, and revenue share are not standardized.

Charge SAR 499 per kiosk per month now, because clinics pay for footfall conversion, not a machine.

Assumption: private clinics and hospitals in Egypt and Saudi Arabia, with some pharmacy-hosted kiosks and a few school/government pilots later. The right launch price is a simple monthly software-and-service fee that the buyer can approve this month; the biggest risk is underpricing a hardware-heavy offer while trust and calibration are still being proven.

At SAR 299, you will win more yeses but leave money on the table. At SAR 699, many clinics will still listen, but you need stronger proof of uptime and paid-report conversion.

1) Offer SAR 499/mo to 10 clinic prospects and record every objection; target 5 verbal yeses. 2) Put SAR 299, SAR 499, and SAR 999 on a one-page sheet and test which tier gets the most serious replies. 3) Close 3 paid pilots at SAR 499/mo and measure scans, uptime, and paid-report conversion weekly. 4) If support exceeds 2 hours per kiosk per month, add a separate SAR 250 setup fee for new installs.

Package the kiosk as a monthly screening service with monitoring, calibration, and report delivery included. Keep hardware sale or lease separate only for buyers who insist on capex; otherwise lead with subscription.

Use a hardware-plus-subscription model: one monthly fee for the kiosk service, plus separate setup or lease terms only when needed. This fits a growing, low-funding founder better than pure device pricing because it creates recurring revenue and easier approvals.

• DIY screening: SAR 0
• Local nurse support: SAR 1,800/mo
• Basic medical device lease: SAR 2,500/mo
• Hospital-grade service contract: SAR 7,000/mo

• SAR 499/mo for one kiosk
• SAR 999/mo for up to 5 kiosks
• Annual site contract for schools and governments

You need about 380 paying sites at SAR 499/mo to make a meaningful base, and the model is still a pilot-stage model, not a forecast.

This blueprint assumes Egypt and Saudi Arabia, with private clinics as the main buyer and pharmacies as hosted distribution points. The pricing is built around a SAR 299 entry tier and a SAR 499 core tier, with annual prepay for schools and larger operators; the biggest risk is trust in readings and whether buyers keep the kiosk active enough to justify recurring fees.

Close 3 clinic pilots at SAR 299 or SAR 499, track scans and paid-report conversion weekly, publish calibration logs on every unit, and test one annual offer with a school or university. By day 30, you should know whether 15 out of 100 scans can upgrade and whether buyers accept the monthly fee.